Non-Small Cell Lung Cancer Market In-Depth Analysis And Future Forecast 2018-2026 | AstraZeneca Plc, F. Hoffmann-La Roche, Eli Lilly and Company, Agennix AG, ArQule

The different, commonly diagnosed types of non-small cell lung cancer (NSCLC) are adenocarcinoma, squamous cell carcinoma, large cell carcinoma, large cell neuroendocrine tumors. Out of all these types adenocarcinoma and squamous cell carcinoma accounts around 60% of lung cancer.

There are no exact reason defined till yet by doctors behind lung cancer but some possible reasons are smoking, air pollution, mineral and metal dust, radiation treatment of chest or breast. The lung cancer symptoms are not noticeable in its early stage because they are considered for other type of illness for example pneumonia or collapsed lung. Some symptoms of lung cancer are chest pain, harsh/raspy sound during breathing, wheezing, weight loss, continuous coughing, hoarseness or voice changes, shortness of breath, lung problems like bronchitis or pneumonia etc. might be the symptoms of lung cancer. Also, if it spreads in other parts of the body then it shows symptoms like bone pain, weakness in arm or leg, yellow skin, yellow eyes, headache and balance problems.

Cancer is the disease in which cell grows abnormally and may cause a tumor. In lung cancer, the cells of lungs starts to grow in uncontrolled manner later form a tumor and can be spread into other body parts. Small cell lung cancer and non-small cell lung cancer are the two main types of lung cancer. As per the stats of Lung Cancer Alliance (leading nonprofit organization dedicated to fighting lung cancer), out of overall lung cancer, around 80 to 85% cases found are of non-small cell lung cancer type and 15-20% cases found are of small cell lung cancer type.

Download the PDF Brochure: www.coherentmarketinsights.com/insight/request-pdf/241

Some diagnosis test are performed by doctors to detect the lung cancer includes diagnostic imaging test like X-ray, MRI, Ultrasound, CT scan and PET scan, also by checking the mucous when the patient cough up for cancer cells which is called as sputum cytology or also by taking the cells of your lungs from abnormal growth area of your lung or from the fluid of lungs which is called as fine needle aspiration biopsy, bronchoscopy and Mediastinoscopy.

Increasing research and development on drugs and the prevalence of lung cancer are the major factors driving the growth of non-small cell lung cancer market
Non-small cell lung cancer is the leading cause of cancer related mortality in U.S. According to the data of American Cancer Society, Inc. (ACSI), NSCLC is the second most common type of cancer found in both men and women. As per the estimation of ACSI, in the year 2017 there will be around 222,500 new cases of lung cancer and 155,870 deaths will happen due to lung cancer in the united states.

The increasing prevalence and incident rate of lung cancer and emerging drugs will drive the market towards positive direction, also the increasing awareness about the treatment will support the growth of non-small cell lung cancer market. There are some growth restraining factors are also available that are less awareness about treatment options in emerging countries, availability of generic drugs, lack of research and development about drugs and increased expenditure on advertisements of tobacco products. According to the stats of IASLC, in 2012 tobacco industry spent $ 9.6 billion on tobacco products advertising and promotion which is 40 times greater than NIH research which spent $ 233 million on lung cancer research.

Some are the leading companies in non-small cell lung cancer are AstraZeneca Plc, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Agennix AG, ArQule Inc, GlaxoSmithKline Pharmaceuticals Limited, Daiichi Sankyo Co. Ltd., Sanofi-Aventis, and Boehringer Ingelheim GmbH. Also as per U.S. Food and Drug Administration some latest drug approvals in Market of non-small cell lung cancer by USFDA are on October 24, 2016 pembrolizumab (Merck & Co., Inc.) received approval, also FDA approved atezolizumab for the treatment of NSCLC on October 18, 2016.

Request A Sample Copy of This Business Report: www.coherentmarketinsights.com/insight/request-sample/241

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr.Shah
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.